Indaptus Therapeutics Inc (INDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has a cash flow conversion efficiency ratio of -1.012x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.19 Million) by net assets ($3.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Indaptus Therapeutics Inc (INDP) net asset quality to measure how much of total assets are equity-financed.
Indaptus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Indaptus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Indaptus Therapeutics Inc (INDP) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Indaptus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indaptus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alligator Bioscience AB
ST:ATORX
|
-3.791x |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
-0.069x |
|
B P Marsh and Partners PLC
LSE:BPM
|
-0.015x |
|
LOBE SCIENCES LTD
F:6YX0
|
N/A |
|
Toys R US ANZ Ltd
AU:TOY
|
0.426x |
|
Sanichi Technology Bhd
KLSE:0133
|
0.025x |
|
Twin Hospitality Group Inc.
NASDAQ:TWNP
|
0.064x |
|
Abrdn UK Smaller Companies Growth Trust PLC
LSE:AUSC
|
0.008x |
Annual Cash Flow Conversion Efficiency for Indaptus Therapeutics Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Indaptus Therapeutics Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Indaptus Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.15 Million | $-14.82 Million | -4.703x | -50.56% |
| 2024-12-31 | $3.94 Million | $-12.32 Million | -3.124x | -181.42% |
| 2023-12-31 | $12.08 Million | $-13.41 Million | -1.110x | -109.05% |
| 2022-12-31 | $24.63 Million | $-13.08 Million | -0.531x | -68.83% |
| 2021-12-31 | $35.90 Million | $-11.29 Million | -0.315x | -102.25% |
| 2020-12-31 | $-237.70K | $-3.32 Million | 13.987x | +655.47% |
| 2019-12-31 | $11.54 Million | $-29.05 Million | -2.518x | -245.03% |
| 2018-12-31 | $53.55 Million | $-39.08 Million | -0.730x | -93.89% |
| 2017-12-31 | $58.80 Million | $-22.13 Million | -0.376x | +28.82% |
| 2016-12-31 | $22.70 Million | $-12.01 Million | -0.529x | -137.68% |
| 2015-12-31 | $35.63 Million | $-7.93 Million | -0.222x | +55.64% |
| 2014-12-31 | $9.48 Million | $-4.75 Million | -0.501x | -37.70% |
| 2013-12-31 | $9.30 Million | $-3.38 Million | -0.364x | +44.59% |
| 2012-12-31 | $6.85 Million | $-4.50 Million | -0.657x | +5.12% |
| 2011-12-31 | $7.77 Million | $-5.38 Million | -0.693x | -84.96% |
| 2010-12-31 | $11.51 Million | $-4.31 Million | -0.375x | +80.86% |
| 2009-12-31 | $1.57 Million | $-3.08 Million | -1.957x | -208.82% |
| 2008-12-31 | $-2.10 Million | $-3.78 Million | 1.798x | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more